CurrentCignaPolicy IP0280

Saphnelo

Cigna coverage policy for Saphnelo (intravenous anifrolumab-fnia) for treatment of moderate to severe systemic lupus erythematosus (SLE) in adults receiving standard therapy; includes prior authorization guidance, approved dosing, and exclusions.

Policy Summary

PayerCigna

PolicySaphnelo

Policy CodePolicy IP0280

Change TypeTitle and appendix updatedno criteria changes

Effective DateJun 15, 2025

Next Review Date

Key ActionObtain prior authorization and document specialist involvement, evidence of autoantibody‑positive SLE, and either concurrent standard therapy or intolerance to standard therapy for approval.

SourceLink

POLICY UPDATE CHANGES

Updated coverage policy title from Anifrolumab-fnia to Lupus Saphnelo and updated Appendix; no criteria changes.

300 mgFDA-approved dose per infusion

every 4 weeksMaximum dosing frequency

6 monthsTypical initial authorization duration

1 yearTypical renewal authorization duration

Approval Criteria for Saphnelo (anifrolumab-fnia)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.